Ono Pharmaceutical Co., Ltd. (4528.T) Stock

4528.T logo

Ono Pharmaceutical Co., Ltd.

4528.TJapan
Healthcare

Company profile

Japan was its largest region in fiscal year 2025, with 61% of revenue. Ono Pharmaceutical reports about 4,206 full-time employees.

What stands out

  • Net income fell 60.9% in fiscal year 2025, from 127.98 billion JPY in fiscal year 2024.
  • It spent 149.87 billion JPY on research and development in fiscal year 2025, 30.8% of its revenue.
  • It was founded in 1717.

Figures from company filings; latest fiscal year ended March 31, 2026.

About Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has strategic collaboration with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; Congruence Therapeutics; and Aitia, Inc. for drug discovery of novel therapeutic targets for neurological diseases. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.

Largest shareholders

  • Ono Pharmaceutical Co., Ltd.4.09%
  • Meiji Yasuda Life Insurance Co.3.73%
  • Ono Shogakukai Foundation3.29%
  • Kakumeiso Co. Ltd.3.24%
  • BlackRock Fund Advisors2.88%

Share of the company, as of September 25, 2026

Leadership

  • Gyo Sagara — CEO & Chairman of the Board, 67
  • Toichi Takino Ph.D. — President, COO & Representative Director, 57
  • Toshihiro Tsujinaka — Corp Sr Ex Off, Chief CMC & Prod, Dig Tech, Glob Qual, Bus Trans Dept Off, Bus Des/Chief Off and Dir, 61
  • Masaki Ito — Corporate Executive Officer, Chief Officer of Fin. & Accounting div.
  • Hirokazu Kitada — Executive VP of Sales & Marketing and Corporate Officer

Where does Ono Pharmaceutical make most of its revenue?

Japan: 61% of revenue by region in fiscal year 2025, followed by USA (34%).

What companies are similar to Ono Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Astellas Pharma Inc. (4503.T), Eisai Co., Ltd. (4523.T), Kyowa Kirin Co., Ltd. (4151.T), Sumitomo Pharma Co., Ltd. (4506.T).

Has Ono Pharmaceutical made a profit in recent years?

Net income by fiscal year: FY2022, 80.52 billion JPY; FY2023, 112.72 billion JPY; FY2024, 127.98 billion JPY; FY2025, 50.05 billion JPY. It was profitable in each of these years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees4,206
Founded1717
IPO DateJun 1, 1963
IPO StatusPublic
HeadquartersOsaka, Japan
FoundersIchibei Ono
ExchangeTokyo
TimezoneAsia/Tokyo (JST)

Contact & Links

Address
8-2, Kyutaromachi 1-chome, Osaka, 541-8564
Phone
81 6 6263 5670
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Ono Pharmaceutical Co., Ltd. (4528.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4528.T

LinkedInLinkedInXXYouTubeYouTube